The present group of articles on the genetic basis of common diseases inaugurates a new policy on the part of the editors of the Proceedings. The editors plan to present a series of written minisymposia on dynamic and emerging areas of research of interest to broad groups of readers. We will solicit and present groups of interrelated articles by leading authorities and contributors describing their perspectives on recent developments in their field. We anticipate that such collections of reviews and discussions will provide a broader perspective' and more insights into the state of a field and the reasons for the current interest in that field that can often be derived from a single review. To broaden the interest in these symposia, the individual articles will be limited in size with an emphasis on changing concepts more than technical details of a subfield. We hope that these collections of reviews will be a resource for a broad group of scientists as well as objects of special interest for the relevant experts.
Understanding the molecular causes for many "simple Mendelian disorders" is one of the great achievements of current biomedical science. The fundamental scheme underlying this advance is simple enough. First, the number of potential "candidate" genes for a disorder must be limited to a small enough number to make analysis feasible. After this, each candidate gene must be examined for evidence of dysfunction manifest by either defective expression or production of an altered protein.
The process of limiting the number of genes to be analyzed can be accomplished by selection of genes whose encoded proteins have catalytic or structural properties relevant to the phenotype of the disease in question or whose alteration is known from spontaneous or experimentally created mutations in animals to create a syndrome resembling that of the disease under study. Alternatively, chromosome abnormalities or genetic analyses can limit the chromosomal region bearing the mutation to a segment whose gene content is sufficiently small for analysis.
Technical improvements are continuing to accumulate relevant to every step of the process of identifying mutant genes. In addition, the accrual of well defined contigs of yeast artificial chromosome, cosmid, or other genomic clones spanning large portions of the genome; the continued accumulation of highly polymorphic genetic markers; and the prospects for rapid accumulation of mapped expressed sequence tags all contribute to the growing number of successes in gene hunting endeavors. Nevertheless, some genetic disorders are laborious or impractical to map by current techniques. For example, hemochromatosis, although one of the most common disorders, maps into a gene-rich region with an unusual degree of extended linkage disequilibrium. This difficult gene can be expected to yield within the next few years. Other disorders are more recalcitrant because the phenotype of the mutant does not suggest obvious candidate genes and the clinical material is not qualitatively or quantitatively appropriate to narrow down the genomic region sufficiently. An extreme example of the last type would be a disease such as progeria (1) that has no obvious candidate genes and that may be a sporadic dominant with all affected individuals infertile. In the future, it is not inconceivable that molecular biologic methods to enrich for DNA fragments bearing sequence variations unique to affected individuals could be developed to the point where even these difficult problems could be approached in an efficient way.
With the reservations described above, the process of identifying genes responsible for penetrant single gene disorders is proceeding at an accelerating rate and predictably will continue to do so until most of the more common disorders have their defects identified, probably within the next few years. In contrast, the major challenge for medical genetics for the next decade is to systematically identify genes responsible for the hereditary contributions to a range of disorders that are not inherited in a simple Mendelian fashion but that have a definite or probable genetic component. The list of these disorders embraces a large fraction of the common causes of disability and death in western society and includes atherosclerosis, hypertension, psychiatric disorders, Alzheimer disease, type I and type II diabetes, asthma, rheumatoid arthritis, 8543 and probably significant components of the general aging process. These disorders may be oligo-or polygenic, and environment and stochastic developmental and immunologic processes may play a major role in development of these diseases.
The problems in defining specific gene variations or mutations that contribute to the propensity for these common complex disorders have been frequently discussed and are multiple and difficult (for example, see ref.
2). Fundamentally, unlike single gene disorders where the data are essentially qualitative, the complex disorders require accurate and unbiased quantitative data and analysis. A partial list of difficulties includes the following: heterogeneity of causation so that nonoverlapping combinations of gene variations may contribute to the increased propensity for the same pathologic process in different individuals (for example, in breast cancer); high incidence of disease-prone genes in the population, so that even in a single family or population isolate the same genes may not be contributing to the disease process in all the affected individuals, as with Alzheimer disease or type II diabetes; a small contribution of any individual gene relative to the total incidence of the disorder, so that large samples are necessary and hidden small biases in selection of the patient and control groups could obscure positive data and make reproducibility difficult, as in the case of the relevance of angiotensin coding mutations in hypertension (3, 4) ; diagnoses based on observations far removed from the basic physiologic process leading to both false-positive and false-negative classification of individuals, as in schizophrenia; even when significant correlations with specific genomic markers are established, the suspect genomic region may be too large for effective investigation of the role of all the embedded genes, as in several of the current insulin-dependent diabetes mellitus gene regions (5) (8); animal models, either based on spontaneous variants or generated by manipulation of embryonic stem cells from mice and regeneration of mutant animals, may confirm deductions from human physiologic studies as to the potential role of particular genes or at least particular pathways but may also produce surprises, as in atherosclerosis (9); confirmation by reconstruction of mutant animals may be confounded by factors such as differences in physiology between species and lack of correlates of the human disease process in animals, as in psychiatric disorders; even when reconstructed mutant mice are informative, precautions are necessary to control for effects of genetic background, linked genes, quantitative variation in gene expression, etc., as is well discussed in a recent review in this journal (9) .
The recently published discussion (9), the following group of reviews, and other recent reviews (4, 10, 11) are remarkable in demonstrating how, in the face of all the above difficulties, major progress is being made in the analysis of disorders such as diabetes, Alzheimer disease, atherosclerosis, hypertension, and congenital malformations. The manner of progress in each area is different in detail and instructive. In atherosclerosis, the general importance of lipoprotein metabolism and specific candidate gene products has been known for some time, and transgenic and knockout animal models (refs. 9 and 11; see also ref. 11 and references therein) have been partially confirmatory of predictions based on human and physiologic studies (although differences in physiology and even the occurrence of a gene limited to primates complicate the issue). In hypertension, major pathways such as the reninangiotensin system have been known for some time, and recent exploitation of this knowledge has led both to paradigmatic transgenic animal studies and to precise definition of allelic variants that contribute to disease incidence (3, 4) . In type I diabetes, initial studies based on the role of class II antigens in immunity led to incrimination of specific amino acid alterations in class II genes as important factors in both animal models (12) and the human disease (5), but further analysis of the genetic contributions to the disease by genome-wide searches has uncovered a number of positive and negative contributory loci, most of which have yet to be reduced to structural variation of specific genes. In Alzheimer disease, positional cloning of genes mutant in early-onset dominant forms of the disease both confirms and extends the knowledge of pathophysiology. A fortunate observation of association of the "sporadic" late-onset disease with certain allelic forms of apolipoprotein E opens further lines of investigation into the pathogenesis of what is perhaps the most common of the classic polygenic diseases (13) . Major successes in assigning mutations responsible for complex dysmorphology syndromes have occurred over the last several years. Here the candidate gene approach has been very successful and is often based on knowledge of families of genes developed from the study of mouse mutations and, strikingly, of Drosophila developmental genetics (14) . In the future, the improvements in technology for constructions of mutant mice with large deletions or substitutions of genetic material offers hope as a powerful approach for defining genes involved in other dysmorphologic disorders, including situations as complex as Down syndrome.
For the near future, increased automation and reduction in financial and time costs will continue to expedite larger scale and more detailed scanning of individual genomes with polymorphic markers. Sample pooling strategies (15) and newer molecular techniques (16) (17) (18) including batch methods for identifying DNA fragments that are identical by descent in pools of individuals may further accelerate this process but remain to be firmly established in practice. What appears more certain is that understanding will continue to progress by synergistic interaction between genetics and molecular functional studies, together with increasing sophistication in the construction of animal models, that luck will be needed and will favor the industrious, and that, as has been uniquely true for molecular biology, over time the optimists will be proven right.
